VXAA-1.1 is under clinical development by Vaxart and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II drugs for Seasonal Influenza have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VXAA-1.1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VXAA-1.1 is under development for the prevention of seasonal influenza adenovector based H1N1 strain A infections. The vaccine candidate is administered through oral route as a coated tablet. It is a monovalent recombinant vaccine consists of a non-replicating adenovirus vector type 5 (Ad5) upon which an adjuvant (TLR3 ligand) is coupled to a target antigen hemagglutinin (HA) from avian influenza.
Vaxart, formerly Aviragen Therapeutics, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, using state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. The company is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer, and dysplasia caused by human papilloma virus (HPV). Vaxart is headquartered in San Francisco, California, the US.
For a complete picture of VXAA-1.1’s drug-specific PTSR and LoA scores, buy the report here.